Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020
03 September 2020 - 10:00PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse, not
manage, disease, announced today that management will participate
in the Advanced Therapies Congress & Expo being held virtually
September 8-11, 2020.
Title: Repair of the microcirculation reverses
ischemic tissue damagePresenter: Douglas W.
Losordo, M.D., EVP, Global Head of R&D and Chief Medical
OfficerTrack: Stem Cells and Regenerative
MedicineDate/Time: Wednesday, September 9, 2020 at
12:00 p.m. (BST)
Title: Roundtable discussion: Development of
regenerative medicines for cardiovascular
indicationsPresenter: David J. Mazzo, Ph.D.,
President and Chief Executive OfficerTrack: Stem
Cells and Regenerative MedicineDate/Time:
Wednesday, September 9, 2020 at 4:00 p.m. (BST)
Additional information can be found on the conference
website.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse, not manage, disease. We are
developing a first- in-class cell therapy product that is based on
the notion that our body contains finely tuned mechanisms for
self-repair. Our technology leverages and enables these mechanisms
in the form of specific cells, using formulations and modes of
delivery unique to each medical indication.
The Company’s current product candidates include CLBS119, a
CD34+ cell therapy product candidate for the repair of lung damage
found in patients with severe COVID-19 infection who experienced
respiratory failure, for which the Company plans to initiate a
clinical trial in the coming weeks as well as three developmental
treatments for ischemic diseases based on its CD34+ cell therapy
platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE
designation and eligible for early conditional approval in Japan
for the treatment of critical limb ischemia (“CLI”) based on the
results of an ongoing clinical trial; CLBS16, the subject of a
recently completed positive Phase 2 clinical trial in the U.S. for
the treatment of coronary microvascular dysfunction (“CMD”); and
CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”)
designated therapy for which the Company has finalized with the
U.S. Food and Drug Administration (the “FDA”) a protocol for a
Phase 3 confirmatory trial in subjects with no-option refractory
disabling angina (“NORDA”). For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084 Email: jmenditto@caladrius.com
Media: W2O Group Christiana Pascale Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024